Addressing Unmet Clinical Challenges for Patients with Prostate Cancer

Tuesday, September 28th 2021 at 1:00 p.m. ET

Predicine was founded in 2015 to address unmet clinical challenges in precision oncology. For patients with metastatic castration-resistant prostate cancer, these challenges include the difficulties of obtaining bone tumor tissue from metastatic sites and the technical challenges in liquid biopsy assays to detect gene deletions.

These challenges create barriers to patients potentially receiving targeted therapies. Over the past several months, Predicine and collaborators have published several manuscripts highlighting the impact of the company’s innovative liquid biopsy solutions to improve care for patients with prostate cancer.

 In this webinar, Predicine’s Founder & CEO, Dr. Shidong Jia, will review data from the recent studies demonstrating the power of Predicine’s innovative liquid biopsy assays to advance the treatment of prostate cancer.  

Date: Tuesday, September 28th
Time: 1:00 PM EDT / 10 AM PDT

Topics to be covered:

  • European Urology
  • Frontiers in Oncology
  • JCO Precision Oncology

Register Now


Title: Addressing Unmet Clinical Challenges for Patients with Prostate Cancer

Date: Tuesday, September 28th, 2021

Time: 1:00pm Eastern Standard Time

Duration: 45 minutes

Speaker:  Dr. Shidong Jia, Founder and CEO of Predicine, Inc.